Skip to main content
. 2020 May 8;39(3):805–823. doi: 10.1007/s10555-020-09885-8

Fig. 2.

Fig. 2

Super-enhancer-driven gene deregulation in cancer can be targeted by CDK7 inhibitors. The super-enhancer landscape in normal cells (a) becomes deregulated in cancer (b), leading to altered gene expression. CDK7 inhibitors preferentially reduce gene expression driven by super-enhancers in cancer cells compared with normal cells (A and B). CDK7i = CDK7 inhibitor